Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRCA-P: Denosumab for prevention of breast cancer in BRCA1 mutation carriers
2017-002505-35Phase 3Active
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer and ductal carcinoma in situ (DCIS) comparing Denosumab with Placebo (2 arms). Primary endpoint: Time to occurrence of any breast cancer (invasive or DCIS). Started May 2018; status: active.
02
Drugs
denosumab
03
Conditions
breast cancerductal carcinoma in situ (DCIS)
Beyond the preview
Go deeper on 2017-002505-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002505-35.